CHCWM – Cancer & Hematology Centers of West Michigan

MGD019 (MacroGenics)

Phase 1, First-in-Human, Open-label, Dose Escalation and cohort expansion study of MGA019, A Bispecific DART Protein Binding PD-1 and CTLA-4 in Patients with Unresectable or Metastatic Neoplasms